Pasithea Therapeutics (KTTA) Competitors

Dare Bioscience (NASDAQ:DARE) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Does the media favor DARE or KTTA?

In the previous week, Dare Bioscience had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 5 mentions for Dare Bioscience and 1 mentions for Pasithea Therapeutics. Dare Bioscience's average media sentiment score of 0.71 beat Pasithea Therapeutics' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in DARE or KTTA?

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 4.0% of Dare Bioscience shares are owned by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, DARE or KTTA?

Dare Bioscience has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Is DARE or KTTA more profitable?

Dare Bioscience's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-8.14%
Pasithea Therapeutics	N/A	-88.14%	-81.21%

Which has higher valuation and earnings, DARE or KTTA?

Dare Bioscience has higher revenue and earnings than Pasithea Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$25.91K	860.78	-$4.05M	-$0.17	-14.82
Pasithea Therapeutics	N/A	N/A	-$13.90M	-$10.60	-0.07

Do analysts recommend DARE or KTTA?

Dare Bioscience presently has a consensus price target of $12.00, indicating a potential upside of 376.19%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pasithea Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dare Bioscience beats Pasithea Therapeutics on 11 of the 14 factors compared between the two stocks.